-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, N56HGcQVNV1R/9s4zBR0kMPKrMGM+TpcJexuRRllAyoje2+SQrd4PwfqdKln8qSd vui/R35dpevaRaQ2IY6LHA== 0001062993-01-000001.txt : 20010122 0001062993-01-000001.hdr.sgml : 20010122 ACCESSION NUMBER: 0001062993-01-000001 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20010103 FILED AS OF DATE: 20010104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NORTRAN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001036141 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: 6-K SEC ACT: SEC FILE NUMBER: 000-29338 FILM NUMBER: 1501786 BUSINESS ADDRESS: STREET 1: 3650 WESBROOK MALL STREET 2: V6S 2L2 CITY: VANCOUVER BC STATE: A1 BUSINESS PHONE: 6042225577 MAIL ADDRESS: STREET 1: 3650 WESBROCK MALL STREET 2: V6S 2L2 CITY: VANCOUVER BC 6-K 1 0001.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of The Securities Exchange Act of 1934 For November 13, 2000 - January 3, 2001 NORTRAN PHARMACEUTICALS ----------------------------------------------- (Translation of Registrant's name into English) 3650 Wesbrook Mall ----------------------------------------------- (Address of principal executive offices) Vancouver, British Columbia, V6S 2L2, CANADA ----------------------------------------------- CIK # 0001036141 FILE NO. 0-29338 ----------------------------------------------- [Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or For 40-F] Form 20-F [x] Form 40-F [ ] [Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange act of 1934.] Yes [x] No [ ] FORM 6-K TABLE OF CONTENTS For November 13, 2000 - January 3, 2001 NORTRAN PHARMACEUTICALS INC. File No. 0-29338, CIK # 0001036141 Exhibit 1 Press Release - Dec. 15, 2000 (Cough Trial Results) Exhibit 2 Material Change Form - December 14, 2000 Exhibit 1 Nortran 3650 Wesbrook Mall Tel: 604-222-5577 Pharmaceuticals Inc. Vancouver, BC Fax: 604-222-6617 V6S 2L2 CANADA Website: www.nortran.com - -------------------------------------------------------------------------------- FOR IMMEDIATE RELEASE TSE: NRT, CDNX: NRT, NASD BB: NTRDF NORTRAN ANNOUNCES COUGH TRIAL RESULTS ------------------------------------- Vancouver, Canada, December 15, 2000 - Nortran Pharmaceuticals Inc. (NRT-TSE) announced today that its anti-cough drug CP1, did not show a statistically significant inhibition of cough in its current Phase II clinical trial. The phase II study assessed the ability of CP1 to reduce cough in patients suffering from "idiopathic cough". "Disappointing results are, unfortunately, a part of the drug discovery business, and experienced at some time or another by every pharmaceutical company," said Bob Rieder, President and CEO. "However, we remain confident about Nortran and its future. Nortran is well financed. Our cardiology program remains very strong with multiple clinical candidates identified, a partnership in place, and an emerging discovery technology platform." The blinded placebo-controlled cross-over phase II trial involved patients selected for heightened sensitivity to cough stimuli, a condition called idiopathic cough. The primary endpoint of the study was to determine whether inhaled CP1 increased the amount of irritant required to induce cough in these sensitive patients. The data showed that CP1 did not significantly increase the amount of irritant required to induce cough. "Intractable cough remains an important unmet medical need and our drug candidate has a novel mechanism of action," Rieder continued. "We will look closely at the data and the cough program over the next few weeks to decide what our next steps should be." Nortran Pharmaceuticals is a drug discovery company focused on cardiovascular and respiratory applications of ion channel modulating drugs. In its program to treat life-threatening cardiac arrhythmia, Nortran has developed several drug candidates suitable for clinical testing as treatments for atrial arrhythmia. Nortran has shown in preclinical studies that its drug candidates are both safe and effective in the suppression of atrial arrhythmia, with little risk of the dangerous side effects associated with current drugs. The company recently achieved one of its most significant corporate milestones by signing the licensing agreement with AstraZeneca PLC. ON BEHALF OF THE BOARD /s/ Bob Rieder Robert Rieder President & Chief Executive Officer WARNING: THE COMPANY RELIES ON LITIGATION PROTECTION FOR "FORWARD-LOOKING" STATEMENTS. THE CANADIAN VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE Exhibit 2 ONTARIO BRITISH COLUMBIA ALBERTA QUEBEC FORM 27 SECURITIES ACT MATERIAL CHANGE REPORT UNDER SECTION 75(2) OF THE SECURITIES ACT (ONTARIO), SECTION 85(1) OF THE SECURITIES ACT (BRITISH COLUMBIA), SECTION 118(1) OF THE SECURITIES ACT (ALBERTA) AND SECTION 73 OF THE SECURITIES ACT (QUEBEC) Item 1. REPORTING ISSUER Nortran Pharmaceuticals Inc. 3650 Wesbrook Mall Vancouver, British Columbia V6S 2L2 Item 2. DATE OF MATERIAL CHANGE December 14, 2000 Item 3. PRESS RELEASE December 14, 2000 - Vancouver, British Columbia Item 4. SUMMARY OF MATERIAL CHANGE The Issuer's anti-cough drug CP1 did not show a statistically significant inhibition of cough in its current phase II clinical trial. Item 5. FULL DESCRIPTION OF MATERIAL CHANGE See press release dated December 14, 2000 for a full description. Item 6. RELIANCE ON SECTION 75(3) OF THE SECURITIES ACT (ONTARIO) AND EQUIVALENT SECTIONS OF OTHER JURISDICTIONS Not Applicable. Item 7. OMITTED INFORMATION Not Applicable. Item 8. SENIOR OFFICER Name: Christina Yip Title: Secretary Phone No.: (604) 222-5577 Item 9. STATEMENT OF SENIOR OFFICER The foregoing accurately discloses the material change referred to herein. Dated at Vancouver, British Columbia, this 19th day of December, 2000. NORTRAN PHARMACEUTICALS INC. Per: /s/ Christina Yip ------------------ Christina Yip Secretary IT IS AN OFFENCE FOR A PERSON TO MAKE A STATEMENT IN A DOCUMENT REQUIRED TO BE FILED OR FURNISHED UNDER THE ACT OR THIS REGULATION THAT, AT THE TIME AND IN THE LIGHT OF THE CIRCUMSTANCES UNDER WHICH IT IS MADE, IS A MISREPRESENTATION. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. NORTRAN PHARMACEUTICALS INC. ---------------------------- (REGISTRANT) Date: January 3, 2001 /s/ Christina Yip ---------------------------- Christina Yip Secretary -----END PRIVACY-ENHANCED MESSAGE-----